GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline announced NDA filings for BRAF inhibitor dabrafenib and MEK inhibitor trametinib in metastatic melanoma on Aug. 3. The two compounds represent one-quarter of the company’s novel oncology agents in clinical development, according to the most recent pipeline update.
You may also be interested in...
Yervoy/Zelboraf Combo Trial Fails, But Sequential Study Continues
Small Phase I melanoma study testing a combination of Zelboraf and Yervoy was closed early due to an unexpectedly high rate of liver toxicity, investigators report in letter to the editor of the New England Journal of Medicine. A sequential study of Yervoy and Zelboraf and other combination studies proceed as planned.
Yervoy/Zelboraf Combo Trial Fails, But Sequential Study Continues
Small Phase I melanoma study testing a combination of Zelboraf and Yervoy was closed early due to an unexpectedly high rate of liver toxicity, investigators report in letter to the editor of the New England Journal of Medicine. A sequential study of Yervoy and Zelboraf and other combination studies proceed as planned.
Precision Medicine And The Advent Of The “Niche Buster”: An Interview With GSK’s Paolo Paoletti
The president of GlaxoSmithKline Oncology talked with “The Pink Sheet” about precision medicine, regulatory climate change, the need to provide value for payers and the company’s commitment to double cancer survival globally over the next 10 years.